Text Size

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

This study has been terminated.
(Interim analyses demonstrated futility. Thus, recruitment curtailed 10/08.)
Sponsor:
Collaborator:
Sanofi
Information provided by:
Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00366301
First received: August 17, 2006
Last updated: October 26, 2010
Last verified: October 2010
History of Changes
Results First Received: October 26, 2010  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Factorial Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Type 2 Diabetes
Interventions: Drug: Insulin glargine injection
Drug: metformin
Drug: Placebo pill

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment occurred at 73 US office-based practices between October 2006 and December 2008.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Preenrollment evaluation comprised local laboratory testing of hsCRP,HbA1c, and safety parameters (ALT or AST and creatinine). Eligible participants were enrolled in a 2-week run-in. Ability to self-monitor fingerstick blood glucose and perform insulin injection was determined and evaluation for evidence of marked hyperglycemia was undertaken.

Reporting Groups
  Description
Placebo Pill Placebo pill
Metformin Pill Metformin pill
Insulin Glargine Plus Placebo Pill Insulin glargine plus placebo pill
Insulin Glargine Plus Metformin Pill Insulin Glargine plus metformin pill

Participant Flow:   Overall Study
    Placebo Pill     Metformin Pill     Insulin Glargine Plus Placebo Pill     Insulin Glargine Plus Metformin Pill  
STARTED     124     126     126     124  
Either 6W or 14W CRP Obtained     120     124     124     119  
COMPLETED     116     120     122     116  
NOT COMPLETED     8     6     4     8  
Lost to Follow-up                 4                 4                 3                 7  
Withdrawal by Subject                 4                 2                 1                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Placebo Pill Placebo pill
Metformin Pill Metformin pill
Insulin Glargine Plus Placebo Pill Insulin glargine plus placebo pill
Insulin Glargine Plus Metformin Pill Insulin Glargine plus metformin pill
Total Total of all reporting groups

Baseline Measures
    Placebo Pill     Metformin Pill     Insulin Glargine Plus Placebo Pill     Insulin Glargine Plus Metformin Pill     Total  
Number of Participants  
[units: participants]
 		  124     126     126     124     500  
Age  
[units: years]
Mean ± Standard Deviation 		         
Mean (SD)     54.0  ± 10.9     53.8  ± 11.5     53.8  ± 11.4     54.0  ± 11.7     53.9  ± 11.4  
Gender  
[units: participants]
 		         
Female     64     68     83     66     281  
Male     60     58     43     58     219  
Ethnicity (NIH/OMB)  
[units: participants]
 		         
Hispanic or Latino     13     4     19     17     53  
Not Hispanic or Latino     110     119     104     105     438  
Unknown or Not Reported     1     3     3     2     9  
Race/Ethnicity, Customized  
[units: Participants]
 		         
White     91     88     95     91     365  
African American     25     34     25     24     108  
Other     8     4     6     9     27  



  Outcome Measures

1.  Primary:   Percentage Reduction in C-reactive Protein (CRP)   [ Time Frame: 14 weeks ]
  Show Outcome Measure 1


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Aruna Pradhan
Organization: Brigham and Women's Hospital
phone: 617-732-8777
e-mail: apradhan@partners.org


No publications provided by Brigham and Women's Hospital

Publications automatically indexed to this study:


Responsible Party: Aruna Das Pradhan, MD, MPH, Brigham & Women's Hospital, Boston, Massachusetts 02115
ClinicalTrials.gov Identifier: NCT00366301     History of Changes
Other Study ID Numbers: 2006-P-000823, Lantus_L_00833
Study First Received: August 17, 2006
Results First Received: October 26, 2010
Last Updated: October 26, 2010
Health Authority: United States: Institutional Review Board